Acumen Pharmaceuticals (ABOS)

• Market cap: $111M
• 1 day: 2.78%
• 5 days: -7.04%
• 1 month: -21.94%
• 3 months: -26.00%
• 6 months: -16.29%
• Year to date: -56.26%
• 1 year: -39.94%
• 5 years: -90.80%
• 10 years: -90.80%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Employees: 52

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

2% more capital invested

Capital invested by funds: $106M [Q2] → $108M (+$1.93M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.11% less ownership

Funds ownership: 72.68% [Q2] → 72.58% (-0.11%) [Q3]

10% less funds holding

Funds holding: 81 [Q2] → 73 (-8) [Q3]

42% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 19

90% less call options, than puts

Call options by funds: $226K | Put options by funds: $2.19M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 711% upside
• Avg. target: $15 711% upside
• High target: $15 711% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target

711% upside $15

Buy Reiterated

13 Nov 2024